ARTICLE
17 October 2024

Teva And MAbxience Add Additional Oncology Biosimilar Candidate, Expanding Strategic Partnership

GP
Goodwin Procter LLP

Contributor

At Goodwin, we partner with our clients to practice law with integrity, ingenuity, agility, and ambition. Our 1,600 lawyers across the United States, Europe, and Asia excel at complex transactions, high-stakes litigation and world-class advisory services in the technology, life sciences, real estate, private equity, and financial industries. Our unique combination of deep experience serving both the innovators and investors in a rapidly changing, technology-driven economy sets us apart.
On October 3, 2024, Teva Pharmaceuticals and mAbxience, a Fresenius Kabi majority-owned group, announced a new global licensing agreement for the development of an anti PD-1 oncology biosimilar candidate, ...
United States Food, Drugs, Healthcare, Life Sciences

On October 3, 2024, Teva Pharmaceuticals and mAbxience, a Fresenius Kabi majority-owned group, announced a new global licensing agreement for the development of an anti PD-1 oncology biosimilar candidate, further strengthening the pair's alliance announced earlier in April of this year. For mAbxience, "this second collaboration is a testament to the strength of our partnership [with Teva]" that "reinforces our commitment to making high-quality biosimilars accessible and improving healthcare outcomes on a global scale," according to CEO Jurgen an Broeck.

Under the terms of this agreement, mAbxience will lead the development and production of the PD-1 oncology biosimilar, utilizing its "state-of-the-art, cGMP compliant facilities in Spain and Argentina." Teva will manage regulatory approvals and oversee commercialization in the designated markets, leading the charge on patient access.

The licensing agreement includes exclusive rights for multiple markets, including Europe and the United States, and aligns with mAbxience's strategy for global expansion. For Teva, the collaboration reflects advancement of its Pivot to Growth strategy by adding a new biosimilar to the company's portfolio, through focused partnerships and business development efforts. According to Dr. Angus Grant, Executive Vice President of Business Development at Teva, "[t]his collaboration with mAbxience reflects Teva's ideal strategic partnership model to optimize development costs, apply our regulatory expertise and leverage our extensive commercial capabilities to bring new treatment options to people living with serious medical conditions."

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More